This clinical-stage biopharmaceutical company has seen no estimate revisions in the last 7 days. The Zacks Consensus Estimate has also remained unchanged over the same time frame. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Kythera currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Investors looking for well-positioned stocks in the biomedical sector may consider Affymetrix Inc. (AFFX), AMAG Pharmaceuticals, Inc. (AMAG) and Biogen Idec Inc. (BIIB). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment